Constraint Identification, Evidence Ranking, and Intervention Mapping

A Decision-Driving Research Document for Formulation Guidance

Status: Evidence map for review. This document identifies constraints and intervention domains; it is not a finished formula and does not constitute a structure/function claim.

Scope note: This whitepaper maps the complete published evidence landscape relevant to nutritional and metabolic intervention in PTSD, including evidence that is weak, conflicting, or disqualifying. The formulation derives from this map; the map is not assembled to justify a pre-chosen formula.

Evidence Level Key

Every constraint and intervention domain in this document is graded against the same scale used in the Solprana neuronal-energy constraint map, to preserve a single internal standard across products.

Level	Definition	Weight in formulation decisions
HIGH	Replicated human clinical (RCT) or direct human biomarker data in PTSD or a defined PTSD subpopulation	Primary basis for action
MODERATE	Human associational/observational data, mixed RCT evidence, or strong mechanistic data without a confirmatory PTSD trial	Supports inclusion with explicit uncertainty
SPECULATIVE	Animal-model or single-study mechanistic data; not validated in humans with PTSD	Investigational only; do not anchor formulation
EXCLUDED	Insufficient, disqualifying, or non-actionable (e.g., a prescription drug, a contradicted mechanism, or a misattributed effect)	Remove from formulation consideration

1. Problem Definition

PTSD is conventionally framed as a fear-and-memory disorder of the central nervous system. That framing is accurate but incomplete. A converging body of clinical and translational evidence reframes PTSD as a systemic bioenergetic and metabolic disorder in which a dysregulated stress response produces a measurable, whole-body failure to restore homeostasis after trauma — with the brain’s fear circuitry as the most visible, but not the only, affected system.

This reframing is not a marketing device. It is supported by three independent review-level syntheses and a mechanistic literature:

• Metabolic-disorder framing. Michopoulos et al. (2016) argue that the neuroendocrine, sympathetic, and metabolic alterations in PTSD resemble those in obesity and type 2 diabetes, and that targeting shared systems (HPA axis, sympathetic nervous system, inflammation) may produce symptomatic relief. Bartoli et al. (2020) reach the same conclusion: PTSD should be approached as a systemic condition, and dysfunctional adaptation to stress increases vulnerability to metabolic abnormalities that in turn favor psychopathology.
• Mitochondrial/bioenergetic mechanism. A 2025 systematic review (43 studies; 29 rodent, 15 clinical) reports reduced ATP, impaired glycolysis, citric-acid-cycle and oxidative-phosphorylation deficits, and elevated oxidative stress in PTSD — concentrated in the hippocampus, amygdala, and prefrontal cortex, the same regions that govern fear processing.
• Lifestyle/metabolic comorbidity. Hall et al. (2015) document that PTSD co-occurs with obesity and cardiometabolic disease and is associated with reduced physical activity and poorer eating behaviors, with preliminary pilot data suggesting diet/activity change can reduce PTSD symptoms.

The relevant formulation question is therefore the same one used across the Solprana portfolio: which biological constraints on homeostasis have sufficient evidence to justify intervention, which have partial evidence warranting inclusion with stated uncertainty, and which should be excluded.

Population scope. The strongest data are in military and veteran populations, where prevalence reaches 25–30% versus 6–7% in the general population. Evidence drawn from civilian, female-only, or mixed-trauma cohorts is flagged where its generalization to combat veterans is uncertain.

2. Constraint Identification and Evidence Ranking

Five biological constraints on homeostasis are identifiable in the PTSD literature. They are not mutually exclusive; they co-occur and interact (Section 4).

Constraint 1 — Glutathione Depletion and Glutamatergic Dysregulation

Evidence level: HIGH. This is the best-evidenced constraint, and the only one with a direct interventional RCT in veterans.

Oxidative stress depletes glutathione, the brain’s primary antioxidant, while impaired prefrontal regulation of basal-ganglia glutamate circuitry sustains the inability to inhibit fear responses. The two are linked: N-acetylcysteine (NAC) is a glutathione precursor that also normalizes extracellular glutamate by restoring glutamate-transporter activity in the nucleus accumbens.

Supporting evidence:

• Back et al. (2016, J Clin Psychiatry): the first RCT of NAC in PTSD. Veterans with PTSD and substance use disorder (N=35) received NAC 2,400 mg/day or placebo plus CBT; NAC produced a significant treatment effect on PTSD symptoms and craving over 8 weeks.
• A multi-centre, double-blind 12-week RCT (Psychiatry Res, 2023) extended this to adjunctive NAC in treatment-resistant PTSD.
• Dell’Oste/Carmassi systematic review (2023): of the antioxidant enzymes examined, glutathione peroxidase was consistently reduced in PTSD across both studies measuring it — the most consistent redox finding in the review, and direct support for the glutathione-depletion mechanism that NAC addresses.

Boundary condition: NAC’s RCT evidence is in comorbid PTSD+SUD and treatment-resistant populations, as an adjunct to therapy, at 2,400 mg/day. Lower doses and non-comorbid populations are less characterized.

Constraint 2 — Magnesium-Dependent Utilization and Fear-Extinction Capacity

Evidence level: HIGH (mechanism) / MODERATE (PTSD-specific intervention).

Magnesium is the obligate cofactor for enzymatically active ATP (Mg-ATP), the functional substrate for the ATPases that maintain neuronal membrane potential. Beyond this general bioenergetic role — established in the Solprana neuronal-energy document — magnesium has a PTSD-specific mechanism: brain magnesium elevation enhances fear-extinction retention.

Supporting evidence:

• Abumaria et al.: elevation of brain magnesium via magnesium-L-threonate enhanced retention of fear extinction without enhancing, impairing, or erasing the original fear memory, by increasing NMDA-receptor signaling and BDNF expression in the infralimbic prefrontal cortex (but not the amygdala) — a region-specific effect on exactly the circuit that defines PTSD.
• Magnesium-deficiency models (Sartori et al.) show HPA-axis dysregulation — elevated CRH transcription and ACTH — reversed by treatment, linking magnesium status to the stress axis.
• Human stress RCTs (e.g., magnesium + vitamin B6 in low-magnesium stressed adults) show reduced perceived stress, with responders defined by deficiency.

Boundary condition: The fear-extinction evidence is preclinical; the human magnesium evidence is in stress/anxiety, not diagnosed PTSD. Effect is deficiency-dependent — repletion of a documented deficit, not general supplementation. Form matters: glycinate or L-threonate for CNS delivery; serum magnesium is not an adequate status marker.

Constraint 3 — Mitochondrial / ATP Throughput Deficit

Evidence level: MODERATE. Strong and convergent at the mechanistic/review level; no nutrient RCT in PTSD.

PTSD models show reduced ATP and impaired oxidative phosphorylation in fear-relevant brain regions. Neurons are metabolically trapped: unlike astrocytes, they cannot compensate for impaired oxidative phosphorylation by upregulating glycolysis, and progressively lose ATP. This is the bioenergetic spine that connects PTSD to the Solprana neuronal-energy framework.

Supporting evidence:

• 2025 systematic review of mitochondrial dysfunction in PTSD: reduced ATP, impaired glycolysis/TCA/OXPHOS, elevated ROS and neuronal apoptosis across 43 studies.
• Frontiers (2023) animal-model review: mitochondrial damage, impaired oxidative metabolism, and elevated hippocampal TNF-α and IL-1β across multiple PTSD models.
• Ketone/metabolic angle: ketone bodies (β-hydroxybutyrate) feed acetyl-CoA directly into the TCA cycle, bypassing the glycolytic bottleneck neurons cannot escape. The Stanford metabolic-psychiatry ketogenic trial (Sethi et al., 2024) demonstrated psychiatric improvement in bipolar/schizophrenia via this metabolic route — adjacent diagnoses, same energy-instability substrate. A small PTSD ketone-feasibility study exists but is not efficacy-powered.

Boundary condition: Mechanistically robust and convergent, but the human PTSD evidence is observational/feasibility-level. Ketogenic intervention is a whole-diet protocol, not a capsule; it informs framing, not a primary formulation component.

Constraint 4 — Neuroinflammation (Heterogeneous)

Evidence level: MODERATE in aggregate; explicitly NOT a reliable standalone biomarker.

This constraint requires the most careful handling, because two systematic reviews appear to disagree and a naive reading would overstate the case.

Supporting evidence and the tension within it:

• Pooled/meta-analytic data (Passos et al., cited in Bartoli 2020) report elevated IL-6 (SMD 0.88), IL-1β (SMD 1.42), IFN-γ (SMD 0.49), and TNF-α (SMD 0.69 in untreated subjects), persisting after excluding comorbid depression. A prospective Marine cohort found each 10-fold rise in baseline CRP associated with OR 1.51 for post-deployment PTSD symptoms — inflammation as predictor, not just correlate.
• Counterweight (Dell’Oste/Carmassi 2023, 44 studies): at the single-study level the cytokine signal is a coin-flip — IL-6 showed no difference in ~59% of studies (20 of 34), IL-1β was elevated in only half, TNF-α in just over half, IFN-γ in 3 of 12.

Reconciliation: a real but small and heterogeneous inflammatory effect appears in pooled analysis yet fails to reach significance in most underpowered single studies (type II error; trauma-type and acute-vs-chronic heterogeneity). The honest position is that inflammation is present in aggregate but is not a reliable standalone biomarker and must not be cited via single markers.

Formulation implication: Neuroinflammation justifies an antioxidant/anti-inflammatory supporting role, not a primary claim. It is downstream of, and overlaps with, the redox constraint (Constraint 1). Address through glutathione/antioxidant support; do not target a cytokine.

Constraint 5 — HPA-Axis Dysregulation and Micronutrient Depletion

Evidence level: MODERATE.

Trauma produces long-lasting changes in HPA-axis regulation, and chronic stress depletes specific micronutrients. Critically, the HPA story is not the intuitive ‘high cortisol’ one.

Supporting evidence:

• Cortisol in PTSD is dysregulated and frequently LOW, not high: pooled data from 37 studies showed no overall difference in plasma/serum cortisol, with decreased levels in females and abuse-related trauma, and a separate meta-analysis found salivary cortisol lower (SMD −0.28). A hypoactive HPA axis prior to trauma may predispose to PTSD by impairing the mobilization of energy resources needed to restore homeostasis — a near-verbatim statement of the Solprana homeostasis thesis.
• Vitamin D: a VA chart review (Brain Sciences, 2025) found >90% of unsupplemented Gulf War veterans deficient (mean 19 ng/mL); repletion to ~30 ng/mL coincided with reduced depression/anxiety in ~80% of the PTSD subgroup. Open-label, uncontrolled, unstructured outcome assessment, with a co-medication confound — deficiency-repletion signal only.
• Vitamin E / omega-3: dietary intake of vitamins E, omega-3 and omega-6 associated with executive function in adults with PTSD (J Affect Disord, 2024) — associational, calling for RCTs.

Critical accuracy requirement: Any Solprana document must describe the HPA axis as dysregulated and often hypoactive — never as a simple high-cortisol state. A ‘high cortisol’ claim is directly contradicted by the meta-analytic record and would be the easiest point to refute.

3. Constraint-to-Intervention Mapping

Each constraint maps to an intervention domain (not a specific product), with evidence level and the key uncertainty stated.

Constraint	Intervention domain	Evidence	Rationale / uncertainty
1. Glutathione / glutamate	Glutathione precursor (NAC)	HIGH	Only ingredient with a direct veteran-PTSD RCT; dual antioxidant + glutamatergic mechanism. Evidence is adjunct-to-therapy, comorbid populations, 2,400 mg/day.
2. Mg-ATP / fear extinction	Intracellular/CNS magnesium (glycinate, L-threonate)	HIGH (mech.) / MOD (PTSD)	Mg-ATP utilization plus region-specific fear-extinction enhancement. Fear-extinction data preclinical; human data in stress/anxiety. Deficiency-dependent; form-dependent.
3. Mitochondrial throughput	Electron-transport cofactors / metabolic (ketone) support	MODERATE	Convergent review-level mechanism; no nutrient RCT in PTSD. Ketogenic protocol is whole-diet, not a capsule — informs framing.
4. Neuroinflammation	Antioxidant / anti-inflammatory support (secondary)	MODERATE (aggregate)	Real in pooled data, heterogeneous per-study. Not a standalone biomarker. Overlaps Constraint 1 — address via redox support, not cytokine targeting.
5. HPA axis / micronutrient depletion	Vitamin D, omega-3, vitamin E, B-complex repletion	MODERATE	Deficiency-repletion logic. Vitamin D data open-label/uncontrolled; omega-3/E associational. HPA must be described as dysregulated/often hypoactive.

Magnesium form selection (carried from the neuronal-energy document)

• Oxide: ~4% absorption; inappropriate for neurological use.
• Citrate / malate: moderate absorption; general repletion.
• Glycinate (bisglycinate): high absorption, reduced laxative effect; sustained neurological repletion.
• L-threonate: superior blood-brain-barrier delivery and the form used in the fear-extinction work; most relevant for the PTSD-specific mechanism.

4. Constraint Interaction and Combination Logic

The five constraints converge on a single pathway and frequently co-occur. The convergence is itself evidence: the inflammation, glutamate, redox, and energy literatures are linked by the kynurenine/NAD+ pathway.

• A unifying mechanism. Stress-induced cytokines upregulate indoleamine 2,3-dioxygenase, shunting tryptophan down the kynurenine pathway toward kynurenic and quinolinic acid (NMDA-active, potentially neurotoxic) while also producing NAD+, the key energy coenzyme. This single pathway links Constraint 4 (inflammation), Constraints 1–2 (glutamate/NMDA), and Constraint 3 (energy/NAD+), and explains the reduced nocturnal melatonin seen in military PTSD (tryptophan diverted from the melatonin route).
• Constraints co-occur. A single patient may carry redox depletion, magnesium-dependent utilization failure, and mitochondrial throughput deficit simultaneously. Addressing one while ignoring the others produces partial benefit at best.
• Non-response is diagnostic, not disqualifying. Failure to respond to one domain identifies which constraint is not dominant in that individual; it does not refute the framework. This mirrors the subgroup logic established for migraine.
• Convergent associational support. Independent populations — a Harvard cohort (Mediterranean diet, fewer PTSD symptoms; Eubacterium eligens as a candidate protective species), a VA chart review (vitamin D), and a nutrient-intake analysis (vitamin E/omega-3) — point to the same plant-forward, antioxidant-rich, deficiency-correcting pattern. Convergence across independent cohorts is more persuasive than any single study.

5. Exclusions and Disqualifications

A complete map states what does not belong. The following are excluded from formulation, with reasons. Several are mechanistically interesting; exclusion is on actionability or evidentiary grounds, not lack of interest.

Agent / mechanism	Reason for exclusion	Disposition
D-cycloserine (NMDA glycine-site agonist)	Prescription drug, not a nutrient. Works only as an acute adjunct to exposure therapy in a narrow dose window (50–125 mg); higher doses are antagonistic, and it can strengthen fear-memory reconsolidation, worsening ‘bad’ exposures.	Excluded. Informs mechanism; the safe, supplement-addressable route to the same NMDA/extinction target is magnesium-L-threonate.
Ibogaine (and the ibogaine + magnesium ‘MISTIC’ protocol)	Schedule I psychoactive drug, administered in Mexico/Canada, with fatal-arrhythmia risk. In the Stanford study (Cherian et al., 2024) the magnesium was CARDIOPROTECTIVE — given to prevent QT prolongation — NOT therapeutic for PTSD. The therapeutic signal is attributed to ibogaine. Study is open-label, uncontrolled, self-referred.	Excluded from mechanism. Use only in the market-context section, with magnesium accurately described as cardioprotective. Do NOT cite the 88% PTSD reduction as magnesium evidence.
Neurotransmitter precursors (5-HTP, L-DOPA, L-tyrosine, GABA)	Patent-grade and vendor evidence only; no controlled PTSD trials. Contradicts the Solprana framework, which excludes neurotransmitter precursors on mechanistic grounds in the neuronal-energy document. Including them would be internally inconsistent.	Excluded for framework consistency.
Single-cytokine targeting	IL-6 and related markers are heterogeneous and bidirectional across studies; global blockade would have off-target effects absent biomarker stratification.	Excluded as a primary claim. Addressed indirectly via antioxidant support.
Vendor/secondary sources (wellness blogs, broad-spectrum micronutrient marketing)	Commercial conflict of interest; not primary literature. Any claim sourced here must be verified against the original RCT before use.	Excluded from the reference list.

Where evidence is genuinely insufficient or missing

• No RCT has tested a multi-constraint nutritional formulation in PTSD with prospective stratification by constraint profile.
• No NAC RCT exists in non-comorbid, non-treatment-resistant PTSD, or in a primary-prevention veteran cohort.
• Magnesium-L-threonate has not been tested in a PTSD-specific human trial despite the preclinical fear-extinction data.
• The largest omega-3 secondary-prevention RCT (DHA after injury) was negative; omega-3 cannot be anchored on.
• Ketone/metabolic intervention in PTSD is feasibility-level only; no efficacy-powered trial.
• The kynurenine/NAD+ pathway is mechanistically compelling but unmeasured as a formulation target in PTSD.

6. Translational Implications for Formulation

The tiers below follow directly from Sections 2–5. The formula derives from this ranking; the ranking is not assembled to fit a formula.

Tier 1 — High Confidence: Primary Intervention Domains

Domain	Constraint	Notes
N-acetylcysteine (glutathione precursor)	1 (redox + glutamate)	The differentiator. Only ingredient with direct veteran-PTSD RCT support, reinforced by the consistent glutathione-peroxidase depletion finding. RCT dose 2,400 mg/day, adjunct to therapy.
Intracellular/CNS magnesium	2 (Mg-ATP + extinction)	Glycinate and/or L-threonate. Mg-ATP utilization plus the PTSD-specific fear-extinction mechanism. Deficiency-targeted; serum Mg not an adequate marker.

Tier 2 — Moderate Confidence: Secondary / Investigational Domains

Domain	Constraint	Notes
Vitamin D repletion	5 (HPA / depletion)	Deficiency-repletion only; open-label VA evidence. Pairs with existing D3/K2 in Happy Health.
Omega-3 (EPA/DHA) + vitamin E	3, 4, 5	Associational (executive function); largest prevention RCT was negative. Include with explicit framing, do not anchor.
Metabolic / ketone support	3 (ATP throughput)	Framework-validated (Stanford, adjacent diagnoses); PTSD evidence feasibility-level. Frames the model; not a primary capsule component.
Gut-brain / plant-forward dietary pattern	4, 5	Harvard cohort (Mediterranean diet, E. eligens). Associational, female cohort. Supports dietary-pattern positioning and Happy Protein, not a specific probiotic claim.

Tier 3 — Speculative: Investigational, Do Not Anchor

Mechanistically aligned with the bioenergetic model and notable because several tie to ingredients Solprana already manufactures, but animal-only — investigational, never a basis for a claim.

• Taurine. Improved potassium ionic homeostasis and mitochondrial function and attenuated PTSD-like symptoms in stress-re-stress rats. Already in Happy Heart Super — a direct cardiac-to-brain mechanistic bridge.
• B-complex / methylation (SAMe + retinoic acid). Reversed PTSD-like behavior in animals via DNMT3a/RORA methylation remodeling. Ties to the methylated B-complex in Happy Health Core.
• Resveratrol; β-alanine. Animal-model improvements in PTSD-like behavior (MAO-A/BDNF; corticosterone/resilience). No human PTSD data.

Summary Decision Table

Mechanism / agent	Evidence	Include?	Condition
NAC (glutathione/glutamate)	HIGH	YES — Tier 1	At/near RCT dose; framed as adjunctive support
Magnesium (CNS-targeted)	HIGH/MOD	YES — Tier 1	Glycinate/threonate; deficiency-targeted
Vitamin D repletion	MODERATE	YES — Tier 2	Documented deficiency only
Omega-3 / vitamin E	MODERATE	OPTIONAL — Tier 2	Associational; do not anchor
Metabolic/ketone support	MODERATE	FRAMING	Whole-diet; not a capsule component
Taurine; B-complex/methylation	SPECULATIVE	INVESTIGATIONAL	Animal-only; already in adjacent products
D-cycloserine; ibogaine	EXCLUDED	NO	Prescription/Schedule I drugs
Neurotransmitter precursors	EXCLUDED	NO	Contradicts framework

7. Regulatory and Document Purpose

• This is a whitepaper, not labeling. It establishes the scientific evidence base independent of any product. Per Solprana practice, the formulation derives from this document; the document does not reference a product and is not a structure/function claim.
• Claim discipline. Dietary-supplement claims must remain structure/function (e.g., supports the body’s normal stress-response and antioxidant capacity), not disease-treatment claims. PTSD is a diagnosable disorder; no Solprana consumer claim may state or imply treatment, cure, or prevention of PTSD. The veteran-PTSD evidence supports the mechanism and the development rationale, not an on-label claim.
• Eating-behavior caution. The PTSD-obesity and disordered-eating literature is citable as context, but no consumer-facing material should translate it into specific dietary prescriptions, targets, or numbers.
• Accuracy commitments carried into all derived content. (1) HPA axis = dysregulated/often hypoactive, never ‘high cortisol.’ (2) Inflammation cited via pooled effect sizes, never single markers, never as a reliable biomarker. (3) The ibogaine study’s magnesium = cardioprotective, never therapeutic. (4) Omega-3 prevention RCT was negative.

Status. Evidence-graded constraint map for review. Two constraints (1, 2) carry sufficient evidence to anchor primary inclusion; three (3, 4, 5) are secondary/investigational; several mechanisms are excluded on actionability or evidentiary grounds. To be updated as constraint-specific human evidence — particularly a magnesium-L-threonate or multi-constraint PTSD trial — becomes available.

References

1. Abumaria N, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. (Magnesium-L-threonate; fear extinction).
2. Back SE, McCauley JL, Korte KJ, et al. A double-blind, randomized, controlled pilot trial of N-acetylcysteine in veterans with PTSD and substance use disorders. J Clin Psychiatry. 2016;77(11):e1439–e1446.
3. Bartoli F, Crocamo C, Carrà G. Metabolic dysfunctions in people with post-traumatic stress disorder. (Review; metabolic/neuroendocrine/inflammatory framing).
4. Cherian KN, Keynan JN, Anker L, et al. Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024. (MISTIC; magnesium cardioprotective).
5. Dell’Oste V, Fantasia S, Gravina D, et al. Metabolic and inflammatory response in PTSD: a systematic review on peripheral neuroimmune biomarkers. Int J Environ Res Public Health. 2023;20(4):2937.
6. Hall KS, Hoerster KD, Yancy WS Jr. Post-traumatic stress disorder, physical activity, and eating behaviors. Epidemiol Rev. 2015;37(1):103–115.
7. Kanaan RA, Oliver G, Dharan A, et al. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-acetylcysteine for treatment-resistant PTSD. Psychiatry Res. 2023;327:115398.
8. Ke S, Wang X-W, Ratanatharathorn A, et al. Association of probable PTSD with dietary pattern and gut microbiome in a cohort of women. Nat Ment Health. 2023. (Mediterranean diet; Eubacterium eligens).
9. Kesavan C, Strong DD, Strong RM. Correction of vitamin D deficiency improves PTSD symptoms in Gulf War veterans. Brain Sci. 2025;15(11):1135. (Open-label VA chart review).
10. Matsuoka Y, et al. Docosahexaenoic acid for selective prevention of PTSD among severely injured patients: a randomized, placebo-controlled trial. (Negative prevention RCT).
11. Michopoulos V, Vester A, Neigh G. Posttraumatic stress disorder: a metabolic disorder in disguise? Exp Neurol. 2016;284:220–229.
12. Mitochondrial dysfunction in PTSD: a mechanism to understand trauma susceptibility? Psychopharmacology. 2025. (Systematic review; 43 studies).
13. Mitochondrial dysfunction in animal models of PTSD. Front Physiol. 2023;14:1105839.
14. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in PTSD: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2:1002–1012.
15. Sartori SB, Whittle N, Hetzenauer A, Singewald N. Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment. Neuropharmacology. 2012;62(1):304–312.
16. Sethi S, et al. Ketogenic diet as a metabolic intervention for serious mental illness. Psychiatry Res. 2024. (Stanford metabolic-psychiatry pilot).
17. Surek M, et al. Supplementation of taurine improves ionic homeostasis and mitochondrial function in rats exhibiting PTSD-like symptoms. (Animal).
18. Warhaftig G, et al. Reduction of DNMT3a and RORA in the nucleus accumbens in PTSD-like behavior: reversal by combinatorial epigenetic therapy (SAMe + retinoic acid). Mol Psychiatry. (Animal).

Note on sources: full citation details (volume/page/PMID) to be completed against the primary records at publication. Secondary/vendor sources reviewed during research were excluded from this list by design.